# BioLineRx Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/BioLineRx Ltd.). ## Overview BioLineRx Ltd. is an Israel-based biopharmaceutical company focused on developing and commercializing therapeutics in oncology and hematology. Its business centers on clinical-stage drug development, licensed and partnered programs, and the commercialization of motixafortide for stem-cell mobilization in the U.S. and selected ex-U.S. markets through collaborators. ## Products & services • APHEXDA® (motixafortide) for stem cell mobilization • Clinical-stage oncology and hematology therapeutics • GLIX1, an oral small-molecule glioblastoma program • Motixafortide development for solid tumors (e.g., PDAC) • Licensing and collaboration arrangements - **Commercialized therapeutics** (30%) — Approved and marketed drug products for hematology indications. - **Clinical-stage oncology programs** (45%) — Drug candidates in clinical development for cancers such as glioblastoma and pancreatic cancer. - **License and collaboration income** (15%) — Partnering arrangements that can generate milestones, royalties, and other non-product income. - **Research and development services** (10%) — Internal and partnered development activities supporting pipeline advancement. - APHEXDA® (motixafortide) for stem cell mobilization - Clinical-stage oncology and hematology therapeutics - GLIX1, an oral small-molecule glioblastoma program - Motixafortide development for solid tumors (e.g., PDAC) - Licensing and collaboration arrangements ## Customers BioLineRx’s direct customers are specialized healthcare providers and treatment centers that use approved hematology products, while its commercialization partner network extends reach across regions. For its pipeline programs, the economic buyers are licensing partners, academic medical centers, and collaborators that fund, study, or commercialize oncology assets. Patient demand is driven by oncology and stem-cell mobilization treatment protocols rather than broad primary-care use. - **Transplant and hematology centers** (primary) — They buy or prescribe APHEXDA for stem-cell mobilization in multiple myeloma patients. - **Oncology hospitals and trial sites** (primary) — They enroll patients into GLIX1 and motixafortide oncology studies and support development. - **Commercial partners** (secondary) — They distribute or commercialize the company's approved product in selected geographies. - **Academic research collaborators** (secondary) — They participate in sponsored and investigator-led clinical development programs. - **Licensing counterparties** (secondary) — They generate milestone and royalty streams tied to partnered assets and territories. - Hematologists and transplant centers using APHEXDA in stem-cell mobilization - Oncology clinicians and hospitals enrolling patients in clinical trials - Commercial partners that market or distribute partnered products - Academic medical centers collaborating on trial execution - Licensees paying milestones or royalties under development deals ## Geography BioLineRx is headquartered in Modi’in, Israel, and maintains an Israeli operating base with U.S. corporate and commercialization activities. The company’s ADSs trade on Nasdaq Capital Market and its ordinary shares trade on the Tel Aviv Stock Exchange, reflecting a dual-capital-market structure. Commercial activity for motixafortide has included the U.S. and partner-led international markets, while clinical development extends across the U.S., Israel, and Europe through collaborations. - **Israel** (40%) — Headquarters, core development activity, and corporate base - **United States** (40%) — Commercialization, clinical operations, and capital markets presence - **Europe** (20%) — Clinical collaboration activity and partner-led research; approximate regional exposure - Headquartered in Modi’in, Israel - U.S. subsidiary supports commercialization and corporate activity - ADSs trade on Nasdaq Capital Market - Ordinary shares trade on Tel Aviv Stock Exchange - Clinical collaboration footprint spans the U.S., Israel, and Europe ## Strategy BioLineRx’s strategy is to advance a small number of differentiated oncology assets through clinical development while monetizing approved or partnered products where possible. The company also uses licensing, collaboration, and regional commercialization partners to extend reach and reduce the operational burden of global launches. Building GLIX1 and expanding motixafortide into additional oncology settings are central to long-duration pipeline value creation. - **Develop GLIX1 in glioblastoma** (medium-term) — A first-in-class program can create pipeline differentiation if clinical data support efficacy and safety. - **Broaden motixafortide into solid tumors** (medium-term) — Expansion into larger oncology settings can extend the asset beyond stem-cell mobilization. - **Leverage commercial partners** (short-term) — Partner-led distribution can widen market access while limiting direct commercial infrastructure needs. - **Maintain optionality through collaborations and licensing** (long-term) — Milestones and royalties diversify funding sources and lower dependence on any single program. - Advance late- and clinical-stage oncology assets - Expand motixafortide beyond stem-cell mobilization - Use partners for regional commercialization - Pursue trial data that can unlock new indications - Supplement value with licensing and royalties ## Risks BioLineRx depends on clinical development success, regulatory execution, and partner commercialization for much of its value creation. Its exposure is concentrated in a small number of oncology assets, so trial setbacks, slower enrollment, or weaker-than-expected market uptake could have an outsized effect. Like other biotech companies, it also faces valuation and impairment risk on intangible assets, financing dependence, and geopolitical or cross-border operating frictions. - **Clinical development setbacks** [high] — Pipeline value depends on proof of safety and efficacy in oncology trials. - **Partner commercialization risk** [high] — Ex-U.S. and some product-market activities rely on third-party execution and market access. - **Intangible asset impairment** [high] — Clinical-stage assets and acquired/indefinite-lived intangibles can be written down if prospects weaken. - **Financing and dilution risk** [high] — Development-stage biotech often requires external capital before programs generate durable cash flow. - **Geopolitical and operating disruption** [medium] — Israel-based operations and global clinical activity can be affected by regional tensions and volatility. - Clinical trial failure or delay could impair pipeline value - Commercial uptake of APHEXDA may be uneven across markets - Partner execution risk affects ex-U.S. monetization - Intangible asset impairment risk is tied to pipeline assumptions - Financing dependence is high for development-stage biotech - Geopolitical and cross-border risks can disrupt operations ## Accounting BioLineRx’s reported results are sensitive to fair-value remeasurement of warrant liabilities, which can create volatility unrelated to operating performance. The company also highlights impairment testing for indefinite-lived intangible assets, making pipeline assumptions and clinical progress important to reported asset values. As a biotech with partnered commercialization and licensing income, judgment around royalties, milestones, and collaboration arrangements can also affect timing and presentation. - **Fair value of warrants** — Can create large non-cash swings in other income/expense - **Indefinite-lived intangible impairment** — Potential write-downs if program value declines - **Royalty and milestone income** — Lumpy income recognition and comparability issues - **Foreign exchange hedging** — Can affect financial expense/income - Warrant fair-value changes can swing non-operating income or expense - Intangible asset impairment depends on pipeline and market assumptions - Milestones and royalties affect timing of non-operating income - FX hedging and NIS-denominated compensation can affect reported expense - IFRS estimates are sensitive to clinical and geopolitical assumptions --- *Last updated: 2026-09-28T11:57:54.507865+00:00*